ATE324904T1 - Verwendung von ghrelin zur behandlung von unterernährung von gastrektomiepatienten - Google Patents

Verwendung von ghrelin zur behandlung von unterernährung von gastrektomiepatienten

Info

Publication number: ATE324904T1
Authority: AT; Austria
Prior art keywords: ghrelin; body weight; gastrectomized; gen; treatment
Prior art date: 2002-10-10

Application number

AT03756447T

Other languages

English (en)

Inventor

John-Olov Jansson

Original Assignee

Gastrotech Pharma As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-10-10

Filing date

2003-10-09

Publication date

2006-06-15

2003-10-09 Application filed by Gastrotech Pharma As filed Critical Gastrotech Pharma As

2006-06-15 Application granted granted Critical

2006-06-15 Publication of ATE324904T1 publication Critical patent/ATE324904T1/de

Links

102000012004 Ghrelin Human genes 0.000 title abstract 3
101800001586 Ghrelin Proteins 0.000 title abstract 3
GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 title abstract 3
208000002720 Malnutrition Diseases 0.000 title 1
238000013110 gastrectomy Methods 0.000 title 1
230000001071 malnutrition Effects 0.000 title 1
235000000824 malnutrition Nutrition 0.000 title 1
208000015380 nutritional deficiency disease Diseases 0.000 title 1
241000700159 Rattus Species 0.000 abstract 2
230000037396 body weight Effects 0.000 abstract 2
208000030814 Eating disease Diseases 0.000 abstract 1
208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
208000015580 Increased body weight Diseases 0.000 abstract 1
241001465754 Metazoa Species 0.000 abstract 1
210000000577 adipose tissue Anatomy 0.000 abstract 1
230000001539 anorectic effect Effects 0.000 abstract 1
206010061428 decreased appetite Diseases 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
230000010534 mechanism of action Effects 0.000 abstract 1
230000000580 secretagogue effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Zoology (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Hematology (AREA)
Diabetes (AREA)
Marine Sciences & Fisheries (AREA)
Obesity (AREA)
Nutrition Science (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Gas Separation By Absorption (AREA)
Solid-Sorbent Or Filter-Aiding Compositions (AREA)

AT03756447T 2002-10-10 2003-10-09 Verwendung von ghrelin zur behandlung von unterernährung von gastrektomiepatienten ATE324904T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP20020022705 EP1407779A1 (de)	2002-10-10	2002-10-10	Verwendung von Ghrelin zur Behandlung von vermindertem Körpergewicht und Körperfett in Individuen mit Gastrektomie

Publications (1)

Publication Number	Publication Date
ATE324904T1 true ATE324904T1 (de)	2006-06-15

Family

ID=32010955

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03756447T ATE324904T1 (de)	2002-10-10	2003-10-09	Verwendung von ghrelin zur behandlung von unterernährung von gastrektomiepatienten

Country Status (9)

Country	Link
US (1)	US7592305B2 (de)
EP (2)	EP1407779A1 (de)
JP (1)	JP4177224B2 (de)
KR (1)	KR20050057650A (de)
CN (1)	CN1723035A (de)
AT (1)	ATE324904T1 (de)
AU (1)	AU2003299710A1 (de)
DE (1)	DE60305055T2 (de)
WO (1)	WO2004032952A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20050071498A (ko) *	2002-09-18	2005-07-07	상트르 오스피딸리에 드 루니버시떼 드 몬트리알	성장 호르몬 방출 호르몬 유사체
USRE42624E1 (en)	2003-06-18	2011-08-16	Tranzyme Pharma Inc.	Methods of using macrocyclic modulators of the ghrelin receptor
JP2007532495A (ja) *	2004-04-07	2007-11-15	ガストロテック・ファルマ・アクティーゼルスカブ	グレリン欠乏を治療するための分泌促進薬の使用
WO2005097174A2 (en) *	2004-04-07	2005-10-20	Gastrotech Pharma A/S	Uses of a combination of ghrelin and somatotropin for the treatment of cachexia
WO2005110463A1 (en) *	2004-05-11	2005-11-24	The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health	Methods of inhibiting proinflammatory cytokine expression using ghrelin
KR101149454B1 (ko) *	2004-08-24	2012-05-25	간가와 겐지	생리활성 펩티드의 액상 제제
WO2006058539A2 (en) *	2004-11-30	2006-06-08	Gastrotech Pharma A/S	Growth hormone secretagogue receptor 1a ligands
KR101510082B1 (ko) *	2006-08-01	2015-04-10	더 스크립스 리서치 인스티튜트	비만증을 억제하기 위한 백신 및 방법
DK2118123T3 (en)	2007-01-31	2016-01-25	Dana Farber Cancer Inst Inc	Stabilized p53 peptides and uses thereof
WO2008100220A1 (en) *	2007-02-14	2008-08-21	Karolinska Innovations Ab	Compositions for increasing body weight, use and methods
US8592377B2 (en)	2007-03-28	2013-11-26	President And Fellows Of Harvard College	Stitched polypeptides
US8324151B2 (en) *	2007-11-20	2012-12-04	The Feinstein Institute For Medical Research	Treatment of sepsis and septic shock using ghrelin and growth hormone
US8013015B2 (en) *	2008-10-02	2011-09-06	Board Of Regents, The University Of Texas System	Small molecule inhibitors of ghrelin O-acyltransferase
JP6057314B2 (ja) *	2010-01-15	2017-01-11	国立大学法人宮崎大学	加療中動物の回復促進治療剤
ES2711526T3 (es)	2010-08-13	2019-05-06	Aileron Therapeutics Inc	Macrociclos peptidomiméticos
EP2672982B1 (de) *	2011-02-09	2019-09-04	The Scripps Research Institute	Hapten-immunkonjugate mit mimetischen ghrelin-polypeptiden von verbesserter löslichkeit und immunogenität sowie verwendungsverfahren dafür
TW201806968A (zh)	2011-10-18	2018-03-01	艾利倫治療公司	擬肽巨環化合物
EP2819688A4 (de)	2012-02-15	2015-10-28	Aileron Therapeutics Inc	Triazol- und thioethervernetzte peptidomimetische makrozyklen
BR112014020103A2 (pt)	2012-02-15	2018-10-09	Aileron Therapeutics, Inc.	macrociclos peptidomiméticos
WO2014071241A1 (en)	2012-11-01	2014-05-08	Aileron Therapeutics, Inc.	Disubstituted amino acids and methods of preparation and use thereof
US20160250224A1 (en) *	2013-09-24	2016-09-01	The Board Of Regents Of The University Of Texas System	Orexin-control of bone formation and loss
EP3197478A4 (de)	2014-09-24	2018-05-30	Aileron Therapeutics, Inc.	Peptidomimetische makrozyklen und verwendungen davon
WO2016154058A1 (en)	2015-03-20	2016-09-29	Aileron Therapeutics, Inc.	Peptidomimetic macrocycles and uses thereof
WO2023161226A1 (en) *	2022-02-22	2023-08-31	Pephexia Therapeutics Aps	Ghrelin agonists with improved potency

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CZ195098A3 (cs)	1995-12-22	1998-10-14	Novo Nordisk A/S	Sloučeniny uvolňující růstový hormon
JP2002505340A (ja)	1998-03-03	2002-02-19	ノボノルディスクアクティーゼルスカブ	（２ｅ）−５−アミノ−５−メチルヘキセ−２−エン酸ｎ−メチル−ｎ−（（１ｒ）−１−（ｎ−メチル−ｎ−（（１ｒ）−１−（メチルカルバモイル）−２−フェニルエチル）カルバモイル）−２−（２−ナフチル）エチル）アミドの新規な塩
JP4142253B2 (ja)	1998-05-11	2008-09-03	ノボノルディスクアクティーゼルスカブ	成長ホルモン放出特性を有する化合物
CZ20011309A3 (cs)	1998-11-03	2001-10-17	Novo Nordisk A/S	Sloučeniny s vlastnostmi uvolňování růstového hormonu
ES2401939T3 (es)	1999-07-23	2013-04-25	Kenji Kangawa	Nuevos péptidos
WO2001056592A1 (en) *	2000-02-01	2001-08-09	Novo Nordisk A/S	Use of compounds for the regulation of food intake
US7244701B2 (en)	2000-06-16	2007-07-17	Zealand Phama A/S	Diuretic peptide conjugate

2002
- 2002-10-10 EP EP20020022705 patent/EP1407779A1/de not_active Withdrawn
2003
- 2003-10-09 WO PCT/DK2003/000679 patent/WO2004032952A1/en not_active Ceased
- 2003-10-09 CN CNA2003801057083A patent/CN1723035A/zh active Pending
- 2003-10-09 KR KR1020057006275A patent/KR20050057650A/ko not_active Withdrawn
- 2003-10-09 US US10/530,866 patent/US7592305B2/en not_active Expired - Fee Related
- 2003-10-09 DE DE60305055T patent/DE60305055T2/de not_active Expired - Lifetime
- 2003-10-09 AU AU2003299710A patent/AU2003299710A1/en not_active Abandoned
- 2003-10-09 AT AT03756447T patent/ATE324904T1/de not_active IP Right Cessation
- 2003-10-09 EP EP03756447A patent/EP1553969B1/de not_active Expired - Lifetime
- 2003-10-10 JP JP2003352592A patent/JP4177224B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
JP4177224B2 (ja)	2008-11-05
US20060217296A1 (en)	2006-09-28
EP1407779A1 (de)	2004-04-14
EP1553969A1 (de)	2005-07-20
WO2004032952A1 (en)	2004-04-22
DE60305055D1 (de)	2006-06-08
US7592305B2 (en)	2009-09-22
DE60305055T2 (de)	2006-12-07
JP2004277402A (ja)	2004-10-07
EP1553969B1 (de)	2006-05-03
KR20050057650A (ko)	2005-06-16
AU2003299710A1 (en)	2004-05-04
CN1723035A (zh)	2006-01-18

Legal Events

Date	Code	Title	Description
2006-11-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE324904T1 (de)	2006-06-15	Verwendung von ghrelin zur behandlung von unterernährung von gastrektomiepatienten
WO2003057269A3 (en)	2004-09-23	Treatment of bioprosthetic tissues to mitigate post implantation calcification
ATE496643T1 (de)	2011-02-15	Verwendung von antioxidantien zur verhinderung von oxidation und zur reduzierung von wirkstoffzersetzung in wirkstoffhaltigen medizinischen artikeln
WO2003072715A3 (en)	2006-11-02	Gasp1: a follistatin domain containing protein
DE60312309D1 (de)	2007-04-19	Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten
ATE477812T1 (de)	2010-09-15	Verwendung von tryptophanreichen peptiden aus molkenproteinhydrolysate zur behandlung von übergewicht und fettleibigkeit
DE602004017888D1 (de)	2009-01-02	Verfahren zur behandlung von akuter und durch übermässige beanspruchung verursachter zerrung und verstauchung mit hyaluronsäure
ATE225803T1 (de)	2002-10-15	Peptid zur verringerung des triglyzeridspiegels des blutes und inhibitor für den anstieg des triglyzeridspiegels des blutes, der das peptid als aktiven bestandteil enthält
TW200501934A (en)	2005-01-16	Therapeutic causing contraction of mucosal tissue, method of treating diseases relating to mucosal tissues, injector and therapeutic set
DE69902520D1 (de)	2002-09-19	Verwendung von selegilin oder desmethylselegilin zur behandlung von wunden, verbrennungen und hautschäden
ATE326534T1 (de)	2006-06-15	Methode zur behandlung von muskelkrankheiten
DE60118769D1 (de)	2006-05-24	Verwendung von langem pentraxin ptx3 zur behanlung von durch geänderte aktivität des fgf-2 wachstumsfaktors hervorgerufene krankheiten
ATE487480T1 (de)	2010-11-15	Perhexilin zur behandlung von chronischer herzinsuffizienz
WO2006013427A3 (en)	2006-06-08	Treatment of ccr2 mediated diseases or disorders
ATE386513T1 (de)	2008-03-15	Verwendung von angelicin und seiner strukturellen analoga zur behandlung von thalassämie
ATE326959T1 (de)	2006-06-15	Verwendung von docosahexaensäure als wirkstoff bei der behandlung von lipodystrophie
AU2003283227A8 (en)	2004-03-29	Method and means for the treatment of vascular and cardiac diseases
EA200600757A1 (ru)	2006-08-25	Тетрапептид, регулирующий уровень глюкозы в крови при сахарном диабете
DE69803298D1 (de)	2002-02-21	Verwendung des wachstumshormons in mitteln zur behandlung der insulinresistenz im herzen
WO2003097690A3 (en)	2004-03-18	Pth derivatives resistant to skin proteases
DE60122781D1 (de)	2006-10-12	Neue therapeutische verwendung eines derivates von thienylcyclohexylamine zur behandlung von schmerzen
Jiang et al.	2002	Inhibitory effect of tibial nerve stimulation on the micturition reflex in the rat
RU2001104774A (ru)	2002-12-27	Способ лечения и профилактики рецидива остеохондроза шейного отдела позвоночника
RU2496531C2 (ru)	2013-10-27	Способ профилактики ротационных контрактур предплечья при переломах лучевой кости в типичном месте
ATE450267T1 (de)	2009-12-15	Verwendung von ginkgo biloba extrakten zur förderung der muskelmasse zum nachteil der fettmasse